Scilex (SCLX) versus Its Competitors Head to Head Contrast

Scilex (NASDAQ:SCLX) is one of 280 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Scilex to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Profitability

This table compares Scilex and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scilex	-244.60%	-437.77%	-112.17%
Scilex Competitors	-4,312.54%	-174.31%	-45.43%

Institutional & Insider Ownership

78.2% of Scilex shares are held by institutional investors. Comparatively, 44.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 8.4% of Scilex shares are held by company insiders. Comparatively, 17.1% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Scilex has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Scilex’s rivals have a beta of 1.03, suggesting that their average share price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Scilex and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	0	0	2	0	3.00
Scilex Competitors	1362	4215	10774	157	2.59

Scilex presently has a consensus target price of $8.00, indicating a potential upside of 471.43%. As a group, “Biological products, except diagnostic” companies have a potential upside of 103.05%. Given Scilex’s stronger consensus rating and higher possible upside, equities analysts clearly believe Scilex is more favorable than its rivals.

Earnings and Valuation

This table compares Scilex and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scilex	$46.74 million	-$114.33 million	-1.09
Scilex Competitors	$521.80 million	-$8.80 million	7.96

Scilex’s rivals have higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Scilex rivals beat Scilex on 8 of the 13 factors compared.

Scilex Company Profile

Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.